Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.51 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.50 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.41 |
| ▸ | HTR3B | O95264 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.41 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.37 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.37 |
| ▸ | KDM4A | O75164 | 1/20 | 0.37 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31286093 | 0.82 | AR (0.45) | P2RX7 | |
| SCHEMBL139341 | 0.79 | MAPK1 (0.47) | IDO1PYCR1 | |
| SCHEMBL30387398 | 0.79 | MAPK1 (0.47) | IDO1PYCR1 | |
| SCHEMBL4021438 | 0.79 | KIF11 (0.45) | P2RX7 | |
| SCHEMBL29170709 | 0.78 | MAPK1 (0.36) | PPARGPPARARAPGEF4 | |
| SCHEMBL460729 | 0.76 | MAPK1 (0.36) | IDO1PYCR1 | |
| SCHEMBL14465785 | 0.76 | S1PR1 (0.37) | PYCR1KDM4AKDM5AKDM5B | |
| SCHEMBL29387410 | 0.76 | MAPK1 (0.36) | IDO1PYCR1 | |
| SCHEMBL120051 | 0.75 | IDO1 (0.61) | IDO1PYCR1HTR3EHTR3BHTR3A | |
| SCHEMBL31731921 | 0.75 | IDO1 (0.61) | IDO1PYCR1HTR3EHTR3BHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2914575-B1 | PLASMINOGEN ACTIVATOR-1 INHIBITORS AND METHODS OF USE THEREOF | UNIV MICHIGAN REGENTS (US) | 2020-10-14 | — | — | EP | disclosed |
| US-20170291893-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF | EASTERN MICHIGAN UNIVERSITY | 2017-10-12 | — | — | US | disclosed |
| US-9718760-B2 | Plasminogen activator inhibitor-1 inhibitors and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-08-01 | — | — | US | disclosed |
| US-20150315178-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-11-05 | — | — | US | disclosed |
| EP-2914575-A1 | PLASMINOGEN ACTIVATOR-1 INHIBITORS AND METHODS OF USE THEREOF | The Regents Of The University Of Michigan (US) | 2015-09-09 | — | — | EP | disclosed |
| WO-2014070983-A1 | PLASMINOGEN ACTIVATOR-1 INHIBITORS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-05-08 | — | — | WO | disclosed |
| US-7183411-B2 | Naphthol, quinoline and isoquinoline-derived urea modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-27 | — | — | US | disclosed |
| US-7183411-B2 | Naphthol, quinoline and isoquinoline-derived urea modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-27 | — | — | US | disclosed |
| US-7183411-B2 | Naphthol, quinoline and isoquinoline-derived urea modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-27 | — | — | US | disclosed |
| US-20040157865-A1 | Naphthol, quinoline and isoquinoline-derived urea modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170291893-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF | SERPINE1, PLAT, SERPINC1 | IDO1 1281/4885PYCR1 1742/4885HTR3E 3354/4885 |
| US-20150315178-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF | SERPINE1, PLAT, SERPINC1 | IDO1 1281/4885PYCR1 1742/4885HTR3E 3354/4885 |
| US-20040157865-A1 | Naphthol, quinoline and isoquinoline-derived urea modulators of vanilloid VR1 receptor | OPRL1, VRK1, OPRK1 | IDO1 1299/4885PYCR1 2760/4885HTR3E 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.